

Reyataz® (atazanavir) - New warning, label updates

- On October 20, 2017, the FDA approved an update to the *Warnings and Precautions* section of the Reyataz (atazanavir) drug label regarding chronic kidney disease.
- Reyataz is indicated for use in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV)-1 infection for patients 3 months and older weighing at least 5 kg.
 - Reyataz is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus.
 - Use of Reyataz/<u>Norvir[®] (ritonavir)</u> in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions.
- Chronic kidney disease in HIV-infected patients treated with Reyataz, with or without Norvir, has been reported during postmarketing surveillance.
 - Reports included biopsy-proven cases of granulomatous interstitial nephritis associated with the deposition of Reyataz drug crystals in the renal parenchyma.
 - Consider alternatives to Reyataz in patients at high risk for renal disease or with preexisting renal disease.
 - Renal laboratory testing (including serum creatinine, estimated creatinine clearance, and urinalysis with microscopic examination) should be conducted in all patients prior to initiating therapy with Reyataz and continued during treatment with Reyataz.
 - Expert consultation is advised for patients who have confirmed renal laboratory abnormalities while taking Reyataz.
 - In patients with progressive kidney disease, discontinuation of Reyataz may be considered.
- In addition, the *Dosage and Administration* section was updated with a subsection regarding testing prior to initiation and during treatment with Reyataz.
 - Renal laboratory testing should be performed in all patients prior to initiation of Reyataz and continued during treatment with Reyataz.
 - Renal laboratory testing should include serum creatinine, estimated creatinine clearance, and urinalysis with microscopic examination.
 - Hepatic laboratory testing should be performed in patients with underlying liver disease prior to initiation of Reyataz and continued during treatment with Reyataz.
- The Contraindications section was also updated to include coadministration with Zepatier™
 (elbasvir/grazoprevir) because concomitant use may increase the risk of alanine aminotransferase elevations due to a significant increase in grazoprevir plasma concentrations.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.